Business Context and Reporting Period
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics targeting Bitter Taste Receptors (TAS2Rs) to treat metabolic diseases, specifically hunger-associated conditions. The reporting period covers the fiscal year ended December 31, 2024. The company is an emerging growth company and a smaller reporting company. In February 2025, the company completed its Initial Public Offering (IPO) on the Nasdaq Global Select Market under the symbol "AARD."
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(20.6) million | $(7.2) million |
| Research & Development Expenses | $17.4 million | $4.5 million |
| General & Administrative Expenses | $5.3 million | $2.2 million |
| Cash, Cash Equivalents, and Short-Term Investments (as of Dec 31, 2024) | $73.7 million | $10.0 million |
| Accumulated Deficit (as of Dec 31, 2024) | $(58.3) million | $(37.7) million |
| Net Cash Used in Operating Activities | $(18.1) million | $(5.8) million |
| Net Cash Provided by Financing Activities | $82.0 million | $0 |
Note: The company has no debt as of December 31, 2024. Liquidity is supported by cash reserves and the net proceeds of approximately $87.5 million from the February 2025 IPO.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses increased by $15.4 million (207%) from 2023 to 2024. This was driven primarily by a $12.9 million increase in R&D expenses due to external costs for chemistry, manufacturing, controls (CMC), clinical, and toxicology studies for the lead candidate ARD-101, and a $3.1 million increase in G&A expenses due to higher personnel and professional costs.
- Capital Raise: In May 2024, the company raised $85.0 million in a Series C financing. Subsequently, in February 2025, the company completed its IPO, raising net proceeds of approximately $87.5 million.
- Credit Losses: Credit losses related to a related party (Aardwolf Therapeutics, Inc.) decreased to $0.1 million in 2024 from $0.8 million in 2023, following the expiration of a Transition Services Agreement in May 2024.
- Other Income: Other income, net, increased to $2.2 million in 2024 from $0.2 million in 2023, primarily due to higher interest income on invested cash.
Guidance, Outlook, and Risks
Outlook and Clinical Progress:
- ARD-101 (Lead Candidate): The company initiated the Phase 3 "HERO" trial for hyperphagia associated with Prader-Willi Syndrome (PWS) in December 2024. Topline data is anticipated in early 2026. The company also plans to initiate a Phase 2 "HONOR" trial for hyperphagia associated with acquired hypothalamic obesity (HO) in the second half of 2025.
- ARD-201: A combination therapy of ARD-101 and a DPP-4 inhibitor for obesity. The company plans to initiate a Phase 2 "EMPOWER" trial in the second half of 2025.
- Liquidity: Management believes existing cash, cash equivalents, short-term investments, and IPO proceeds will fund operations into 2027.
Risks and Contingencies:
- Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to a lack of segregation of duties and insufficient qualified resources. A remediation plan is underway, including hiring additional personnel and implementing a new ERP system.
- Capital Requirements: The company has incurred significant losses since inception and expects to continue incurring losses. It will require substantial additional financing to complete development and commercialization.
- Clinical Trial Risks: Success depends on the successful completion of clinical trials, which are uncertain in timing and outcome. Enrollment in trials for rare diseases like PWS may be challenging.
- Regulatory Risks: The company has not previously submitted a New Drug Application (NDA). Regulatory approval is not guaranteed.
Key Facts for Investor Verification
- Phase 3 Trial Initiation: Verify the enrollment status and progress of the Phase 3 HERO trial for ARD-101 in PWS, initiated in December 2024.
- Internal Control Remediation: Monitor the company's progress in remediating the identified material weakness in internal controls over financial reporting.
- Cash Burn Rate: Track the rate of cash consumption against the projected runway into 2027 to assess the need for future dilutive financing.
- Related Party Transactions: Review the status of the $1.4 million receivable and $1.0 million note from Aardwolf Therapeutics, Inc., which have been written off as uncollectible.
- Intellectual Property: Confirm the status of patent applications and the potential for patent term extensions for ARD-101 and ARD-201.